Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy-induced nausea and vomiting (RINV): CTRI/2022/01/039723. PNQ ≥D 3 months after end of PTX 32.0% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback